Tibolone and risk of ovarian and endometrial cancer

Background: Use of unopposed estrogen therapy or combined estrogen/progestin therapy increase ovarian cancer risk. For endometrial cancer addition of continuous progestin decrease the estrogen induced increased risk. Less in known about the influence of tibolone a synthetic steroid with estrogenic, progestagenic, and androgenic properties.